The research company Hamlet Biopharma states that the negotiations with a leading German player on a partnership for the development and commercialization of the drug candidate Alpha1H are proceeding according to plan.The company announces that the due diligence process has now been completed and that the commercial negotiations are focusing on the terms and framework for the development and commercialization of Alpha1H for the treatment of bladder cancer in Europe and several other markets. At the same time, discussions are also under way about commercialization in additional markets with the aim of achieving a global launch.The German player previously signed a non-binding letter of intent with Hamlet Biopharma.